Skip to content

Lori L. Davis

Birmingham VA Medical Center

2 papers in the library · 14 citations · publishing 2025-2026

Papers

A systematic review of income and education reporting in psychedelic clinical trials

Nature Mental Health May 1, 2025 Daniel H. Grossman, Kevin R. Madden, Nicky J. Mehtani et al. 10 citations

Socioeconomic status (SES) strongly affects mental health outcomes and treatment access, but its reporting in psychedelic-assisted therapy trials is inadequate. A systematic review of 98 articles (49 primary trials and 49 secondary analyses) from 2006 to 2024 found that only 12% of primary trials reported participant income data, and 31% reported educational attainment. In US-based trials, participants had markedly higher SES than the general population: 93% had some college education (versus 62% nationally), and median incomes in major trials substantially exceeded the national median for all workers. Non-US trials showed variable patterns. This underreporting and evidence of socioeconomic disparities highlights an urgent need for standardized SES reporting and strategies to improve socioeconomic diversity in psychedelic-assisted therapy research.

Psilocybin in the Treatment of Cocaine Use Disorder

JAMA Network Open May 7, 2026 Peter S. Hendricks, Sara Lappan, Richard C. Shelton et al. 4 citations

A single 25 mg dose of psilocybin, combined with psychotherapy, led to a higher percentage of cocaine-abstinent days, a greater likelihood of complete abstinence, and a longer time before the first cocaine lapse over 180 days compared with an active placebo (100 mg diphenhydramine) in a randomized, quadruple-blind trial. Among 40 participants with cocaine use disorder, 33 were men, 33 were Black, and most had low income. Psilocybin appeared safe, with no serious adverse events, and may offer a treatment for cocaine use disorder in underrepresented populations.